267 related articles for article (PubMed ID: 31167178)
1. Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies.
Gafter-Gvili A; Tibau A; Raanani P; Shepshelovich D
Acta Haematol; 2020; 143(1):73-77. PubMed ID: 31167178
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
[TBL] [Abstract][Full Text] [Related]
3. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
[TBL] [Abstract][Full Text] [Related]
4. Twenty Years of Targeted and Biologic Immunomodulatory Drugs: Postmarketing Modifications of Drug Labels Approved by the US Food and Drug Administration.
Berman J; Yavne Y; Edel Y; Elkayam O; Furer V; Shepshelovich D
Mayo Clin Proc; 2022 Aug; 97(8):1512-1522. PubMed ID: 35933136
[TBL] [Abstract][Full Text] [Related]
5. Postmarketing Safety of Vaccines Approved by the U.S. Food and Drug Administration : A Cohort Study.
Tau N; Yahav D; Shepshelovich D
Ann Intern Med; 2020 Sep; 173(6):445-449. PubMed ID: 32716700
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018.
Fan M; Chan AYL; Yan VKC; Tong X; Lau LKW; Wan EYF; Tam EYT; Ip P; Lum TY; Wong ICK; Li X
Orphanet J Rare Dis; 2022 Jan; 17(1):3. PubMed ID: 34983612
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
Kesselheim AS; Myers JA; Avorn J
JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
[TBL] [Abstract][Full Text] [Related]
9. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
Mostaghim SR; Gagne JJ; Kesselheim AS
BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
[No Abstract] [Full Text] [Related]
10. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
11. Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugs.
Ikeda J; Kaneko M; Narukawa M
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1393-1401. PubMed ID: 30094880
[TBL] [Abstract][Full Text] [Related]
12. Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases.
Nagai S; Ozawa K
Invest New Drugs; 2018 Jun; 36(3):487-495. PubMed ID: 29453626
[TBL] [Abstract][Full Text] [Related]
13. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
Wallach JD; Ross JS; Naci H
Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
[TBL] [Abstract][Full Text] [Related]
14. Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014.
Pinnow E; Amr S; Bentzen SM; Brajovic S; Hungerford L; St George DM; Dal Pan G
Clin Pharmacol Ther; 2018 Aug; 104(2):390-400. PubMed ID: 29266187
[TBL] [Abstract][Full Text] [Related]
15. Timing of new black box warnings and withdrawals for prescription medications.
Lasser KE; Allen PD; Woolhandler SJ; Himmelstein DU; Wolfe SM; Bor DH
JAMA; 2002 May; 287(17):2215-20. PubMed ID: 11980521
[TBL] [Abstract][Full Text] [Related]
16. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
[TBL] [Abstract][Full Text] [Related]
17. Postmarketing surveillance for oncology drugs.
Viale PH; Moore S
Clin J Oncol Nurs; 2008 Dec; 12(6):877-86. PubMed ID: 19064381
[TBL] [Abstract][Full Text] [Related]
18. Rare cancer trial design: lessons from FDA approvals.
Gaddipati H; Liu K; Pariser A; Pazdur R
Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
[TBL] [Abstract][Full Text] [Related]
20. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]